Join the 200th Anniversary Celebration

Original Article

CISH and Susceptibility to Infectious Diseases

Chiea C. Khor, M.B., B.S., D.Phil., Fredrik O. Vannberg, D.Phil., Stephen J. Chapman, M.R.C.P., Haiyan Guo, Ph.D., Sunny H. Wong, M.B., Ch.B., Andrew J. Walley, D.Phil., Damjan Vukcevic, D.Phil., Anna Rautanen, Ph.D., Tara C. Mills, B.S., Kwok-Chiu Chang, M.B., B.S., Kai-Man Kam, M.B., B.S., Amelia C. Crampin, M.B., Ch.B., Bagrey Ngwira, M.B., B.S., Ph.D., Chi-Chiu Leung, M.B., Cheuk-Ming Tam, M.B., B.S., Chiu-Yeung Chan, Ph.D., Joseph J.Y. Sung, F.R.C.P., Ph.D., Wing-Wai Yew, M.B., F.C.C.P., Kai-Yee Toh, B.S., Stacey K.H. Tay, M.R.C.P.C.H., Dominic Kwiatkowski, M.D., Ph.D., Christian Lienhardt, M.D., Tran-Tinh Hien, M.D., Ph.D., Nicholas P. Day, B.M., B.Ch., Nobert Peshu, M.B., Ch.B., Kevin Marsh, F.R.C.P., Kathryn Maitland, M.D., Ph.D., J. Anthony Scott, F.R.C.P., Thomas N. Williams, M.D., Ph.D., James A. Berkley, F.R.C.P.C.H., Sian Floyd, M.Sc., Nelson L.S. Tang, F.R.C.P.A., Paul E.M. Fine, Ph.D., Denise L.M. Goh, M.R.C.P.C.H., and Adrian V.S. Hill, F.R.C.P., D.M.

N Engl J Med 2010; 362:2092-2101June 3, 2010

Abstract

Background

The interleukin-2–mediated immune response is critical for host defense against infectious pathogens. Cytokine-inducible SRC homology 2 (SH2) domain protein (CISH), a suppressor of cytokine signaling, controls interleukin-2 signaling.

Methods

Using a case–control design, we tested for an association between CISH polymorphisms and susceptibility to major infectious diseases (bacteremia, tuberculosis, and severe malaria) in blood samples from 8402 persons in Gambia, Hong Kong, Kenya, Malawi, and Vietnam. We had previously tested 20 other immune-related genes in one or more of these sample collections.

Results

We observed associations between variant alleles of multiple CISH polymorphisms and increased susceptibility to each infectious disease in each of the study populations. When all five single-nucleotide polymorphisms (SNPs) (at positions −639, −292, −163, +1320, and +3415 [all relative to CISH]) within the CISH-associated locus were considered together in a multiple-SNP score, we found an association between CISH genetic variants and susceptibility to bacteremia, malaria, and tuberculosis (P=3.8×10−11 for all comparisons), with −292 accounting for most of the association signal (P=4.58×10−7). Peripheral-blood mononuclear cells obtained from adult subjects carrying the −292 variant, as compared with wild-type cells, showed a muted response to the stimulation of interleukin-2 production — that is, 25 to 40% less CISH expression.

Conclusions

Variants of CISH are associated with susceptibility to diseases caused by diverse infectious pathogens, suggesting that negative regulators of cytokine signaling have a role in immunity against various infectious diseases. The overall risk of one of these infectious diseases was increased by at least 18% among persons carrying the variant CISH alleles.

Media in This Article

Figure 1Single-Nucleotide Polymorphisms Genotyped within CISH and Its 2-Mb Flanking Region.
Figure 2Odds Ratio for the Variant Allele CISH−292, According to Study Population.
Article

Tuberculosis, malaria, and invasive bacterial disease together account for more than 5 million deaths annually in the developing world. Although a significant proportion of interindividual variation in disease susceptibility can be attributed to environmental factors such as malnutrition and infection with the human immunodeficiency virus (HIV), a substantial portion is unexplained. Comparative studies involving twins and adopted persons suggest a genetic component,1 and genes that, when mutated, result in primary immunodeficiency states have been identified. Such immunodeficiencies are extremely rare, however, and the current understanding of common host genetic factors influencing susceptibility to major infectious diseases at the population level is limited.

A principal feature of the host immune response to infection by structurally diverse pathogens is the inflammatory cytokine response.2-4 The proinflammatory cytokine interleukin-2 determines the magnitude and duration of the T-cell response immediately after antigen encounter5 and assists in the maturation of macrophages and the proliferation of B cells and natural killer cells6 in the early stages of the adaptive immune response. Interleukin-2 also regulates the evolution of memory T cells after resolution of infection.7 An excessive cytokine-mediated inflammatory response can be harmful to the host, resulting in severe forms of malaria and sepsis.8-11

Control of cytokine signaling in humans is mediated in part by negative feedback from the suppressor of cytokine signaling (SOCS) family of proteins. Cytokine-inducible SRC homology 2 (SH2) domain protein (CISH) was the first member of the SOCS family to be described.12,13 CISH is the gene most consistently up-regulated by interleukin-2 stimulation in humans,14 and it appears to be critical for T-cell proliferation and survival15 in response to infection. CISH controls the signaling of a variety of cytokines, in particular interleukin-2. Unlike the other members of the SOCS family, CISH binds to the phosphorylated tyrosine residues of cytokine receptors and masks sites at which the signal transducer and activator of transcription 5 (STAT5) would otherwise dock.12,16-19 Thus, increased CISH activity blocks the cytoplasmic docking and activation of STAT5 and thereby inhibits downstream cytokine signaling. Given the central role of CISH in controlling interleukin-2 signaling, we hypothesized that variation in CISH influences susceptibility to common infectious diseases.

Methods

Subjects

We analyzed data on 8402 persons from seven case–control series (Table 1Table 1Characteristics of the 8402 Subjects Enrolled in the Study.). These persons included Kenyan children with bacteremia20; persons with tuberculosis from Malawi,21 Hong Kong,22 and Gambia23; and persons with severe malaria from Gambia,24 Kenya,25 and Vietnam.8 We obtained written informed consent from the study participants or their parents or guardians and ethics approval from the relevant national authorities for all study collections (see the Supplementary Appendix, available with the full text of this article at NEJM.org). We obtained blood samples from which we extracted DNA (see the Supplementary Appendix). Controls were geographically matched to the cases. Twenty other immune-related genes have been studied previously in one or more of these sample collections (see the Supplementary Appendix).

Genotyping, Cell Stimulation, and Gene Expression

We used standard methods for genotyping (see the Supplementary Appendix). We purified peripheral-blood mononuclear cells (PBMCs) from whole blood obtained from the subjects, cultured these cells, and then stimulated them with interleukin-2 or interleukin-3. We harvested the PBMCs at 0, 30, 60, and 120 minutes after the addition of interleukin; extracted RNA using a standard method; and synthesized and assayed complementary DNA using a real-time polymerase-chain-reaction assay (Supplementary Appendix).

Statistical Analysis

Power calculations for all case–control studies are included in Figure 1 in the Supplementary Appendix. A comparison of allele frequencies according to the different genetic patterns of inheritance between case subjects and controls was performed with Pearson's chi-square test. The most likely pattern of inheritance was determined on the basis of the best-fitting model with the use of logistic regression. Detailed descriptions of the statistical procedures, as well as of the various patterns of inheritance, are included in the Supplementary Appendix. Analysis of pairwise linkage disequilibrium between single-nucleotide polymorphisms (SNPs) was performed with the use of the r2 algorithm in Haploview software, version 3.2.26 The multiple-SNP score was analyzed as previously described for case–control populations.27 Subjects were classified according to the number of risk alleles they carried (0, 1, 2, 3, or ≥4). A trend test for association was then performed.28 Our analysis of gene-expression data is included in the Supplementary Appendix.

Results

Genetic Analysis of CISH

CISH comprises four exons, of which exons 2 to 4 encode the CISH protein. We sequenced CISH (1000 bp upstream of the transcription start to the end of exon 4, including introns) in 24 case subjects and 24 controls from the Kenyan Bacteremia Study. The power to detect SNPs with a minor-allele frequency of 0.05 was 99.3% (Figure 2 in the Supplementary Appendix). We identified eight SNPs with a minor-allele frequency greater than 5% (Figure 3A in the Supplementary Appendix), and we did not detect any new coding changes or predicted splice-junction variants. We then genotyped these eight SNPs in the case–control Kenyan Bacteremia Study. Four of these SNPs (at positions −639, −292, −163, and +3415) showed evidence of association (P=0.02 to P=1.0×10−3) (Figure 1Figure 1Single-Nucleotide Polymorphisms Genotyped within CISH and Its 2-Mb Flanking Region. and Table 2Table 2Results of Single-Nucleotide Polymorphism (SNP) Analysis of CISH. ); the variant alleles at each SNP were associated with an increased susceptibility to bacteremia. Adjustment for HIV status, malnutrition, and age did not significantly affect these associations.

We observed low pairwise linkage disequilibrium between SNPs at positions −639 and +3415, between these SNPs and those that lie between them, and between the SNPs that lie between them (r2<0.50) (Figure 3B in the Supplementary Appendix). We also observed associations between multiple SNPs and susceptibility to disease, and bearing in mind the low pairwise linkage disequilibrium between these SNPs, we hypothesized that the risk alleles at these SNPs confer susceptibility independently of one another. To investigate whether the risk of disease increased in an allele dose-dependent manner with respect to the number of risk alleles, we determined multiple-SNP scores for the five SNPs.26 We observed that the risk of bacteremia was proportionate to the number of risk alleles carried (P=5.1×10−5) (see the Supplementary Appendix). The haplotype analysis was uninformative, presumably because of the low intermarker linkage disequilibrium. We did not observe any significant interaction among the five SNPs, and we went on to genotype them in the remaining six case–control studies.

In the Malawian Tuberculosis Study, the minor alleles of three SNPs (−292, +1320, and +3415) were associated with increased susceptibility to tuberculosis (P=0.01 to P=5.0×10−3) (Figure 1 and Table 2). For +1320 (P=6.0×10−3), the effect of the risk allele appeared to be strongest with a recessive pattern of inheritance. Persons who were homozygous for the risk allele were significantly more susceptible to tuberculosis than matched controls (5.6% of case subjects were homozygous for the risk allele, as compared with 1.9% of controls; P=5.0×10−3). Adjustment for the potential confounding effects of age, sex, and race or ethnic group did not affect the degree of statistical significance or odds ratio for each SNP. The trend test also showed an increase in the risk of disease with an increase in the number of risk alleles (P=0.03) (see the Supplementary Appendix). In the Hong Kong Tuberculosis Study, persons with tuberculosis were more likely to carry variant CISH alleles (at positions −292 and +1320) than were unaffected persons (P=0.03 and P=2.0×10−3, respectively). In the case–control Gambian Tuberculosis Study, we observed an association between the CISH +1320 variant allele (but not the −292 SNP variant allele) and susceptibility to clinical tuberculosis (P=0.03). The positive trend test for tuberculosis observed in the Malawian Tuberculosis Study was replicated in both the Hong Kong Tuberculosis Study (P=0.01) and the Gambian Tuberculosis Study (P=0.03).

We genotyped the five CISH SNPs in three sample collections obtained from subjects with severe malaria in the Gambian Malaria Study, the Kenyan Malaria Study, and the Vietnam Malaria Study. The variant alleles at positions −639, −292, +1320, and +3415 showed a significant association with increased susceptibility to disease. In particular, the minor allele at position −292 showed a significant association with susceptibility to severe malaria in the Gambian Malaria Study, the Kenyan Malaria Study, and the smaller Vietnam Malaria Study (Table 2). The trend toward an increase in disease risk with an increasing number of CISH risk alleles observed in the bacteremia and tuberculosis studies was replicated in all three malaria studies (see the Supplementary Appendix).

To investigate the possibility that the associated SNPs might be in linkage disequilibrium with causative variants, we performed exclusion mapping by genotyping 28 additional SNPs spanning 2 million bp in the chromosome 3p21 region surrounding CISH in the Malawian Tuberculosis Study population. None of these 28 SNPs showed evidence of association with tuberculosis (Figure 1).

On pooled analysis, the carriage of CISH risk alleles at −639, −292, −163, +1320, and +3415 was associated with increased susceptibility to the infectious diseases studied (Table 2), with −292 accounting for most of the association signal (P=4.58×10−7) (Table 2 and Figure 2Figure 2Odds Ratio for the Variant Allele CISH−292, According to Study Population.). Multiple-SNP scoring of the five SNPs in each case–control study revealed a correlation between the number of CISH risk alleles and the risk of disease (P=3.8×10−11 for trend) (see the Supplementary Appendix). In persons carrying one or more risk alleles, the overall risk was increased by at least 18%.

Functional Analysis of CISH

We studied the functional effects of the CISH promoter variants because these SNPs showed the strongest associations with disease and they are more likely to affect gene expression than intragenic SNPs. We genotyped the promoter SNPs at positions −639, −292, and −163 in 400 healthy adult subjects of Han Chinese descent. The observed risk-allele frequency for the SNPs at positions −292 and −163 was 41.5% and 6.1%, respectively, and only a single subject was homozygous for the variant allele at position −163; SNP −639 was not polymorphic in these persons, a finding that is consistent with observations from the Hong Kong Chinese case–control study. We first examined the individual effects of SNPs −292 and −163 on CISH gene expression in human PBMCs after stimulation with interleukin-2 at a final concentration of 100 U per milliliter. Since levels of expression of the wild-type CISH −292AA and carrier CISH −292AT genotypes did not differ significantly, we questioned whether this SNP might exert a recessive effect. As shown in Figure 3AFigure 3Expression of CISH−292 in Response to Stimulation with Interleukin-2., the 10 persons who were homozygous for the variant CISH −292TT risk genotype had significantly lower levels of CISH than the 5 persons who were homozygous for the alternative allele (AA) and the 10 heterozygous carriers (AT) at 30, 60, and 120 minutes after stimulation with interleukin-2. We did not observe any difference in CISH expression (with respect to the CISH −292 genotype) after stimulation with interleukin-3. Nor did we observe a significant genotype-specific difference according to allelic variation at position −163 after stimulating cells with either interleukin-2 or interleukin-3 (data not shown).

To test for an interactive effect between CISH −292 and CISH −163, we determined two SNP diplotypes, −292 and −163, for the subjects in whom CISH expression was assessed (with the chromosomal phase determined by subcloning and sequencing for persons with a chromosomal phase that was uncertain), and we then compared CISH expression between the −292 genotypes in response to interleukin-2 stimulation, using −163 as the conditioning locus. For persons who were homozygous for the major (nonrisk) allele at −163, carriage of the variant −292TT genotype resulted in markedly lower overall gene expression (25 to 40% lower) in response to interleukin-2 stimulation at all time points (Figure 3B). We observed no significant differences in CISH expression after stimulation by interleukin-2 or interleukin-3 when we compared the other CISH diplotypes with one another (data not shown).

Discussion

We identified a panel of five CISH SNPs associated with increased susceptibility to bacteremia, tuberculosis, and malaria, and we estimated that the overall risk of one of these infectious diseases was increased by 18% among persons carrying a single CISH “risk” allele. This risk increased to 81% among persons with four or more risk alleles (see the Supplementary Appendix).

Two important considerations in genetic association studies are population stratification and multiple testing. To assess the presence of population stratification, we examined 28 independent markers in the 2-Mb region flanking CISH, and we did not detect significant inflation of test statistics (genomic inflation factor, 1.03). Furthermore, the consistency of the association across multiple racial and ethnic groups argues against the results being a product of population stratification. To account for multiple testing, we evaluated CISH in the context of 20 other immune-related genes (analyzing a total of 187 SNPs) previously tested in one or more of these sample collections (see the Supplementary Appendix); the single-point observation with CISH −292 (P=4.58×10−7) remained significant after correction for all the genes and SNPs tested (the threshold P value after correction for multiple testing is 10−4, with each of the 187 SNPs tested on average 2.7 times). The false positive report probability29 for −292 was 10−4 or less even at previous probability levels of 10−5 or less. Further confidence is lent by the very low P value (<5×10−11) observed with the multiple-SNP score and the level of replication among study groups.

The pattern of association with CISH −292 was consistently reproducible across six of the seven study groups, with the exception of the Gambian Tuberculosis Study. One possible explanation for this heterogeneity is that disease susceptibility was accounted for by more than one SNP within the five-SNP panel, thus rendering the single-SNP analysis incomplete. A second reason might relate to the underlying population structure, where different CISH SNPs may tag the informative variants in each distinct population. A third possibility is that there remain unidentified functional SNPs within the region of association delineated by the five-SNP panel that also account for association with disease. This last possibility is unlikely, however, since direct sequencing did not detect additional putatively functional polymorphisms. To explore the first and second possibilities, we used multiple-SNP scoring for all five associated SNPs. The risk of disease increased markedly with an increase in the number of risk alleles carried in each population. Since this multiple-SNP analysis was more informative, with respect to risk, than analyses of single SNPs in isolation, the first two possibilities remain plausible explanations. The mechanisms underlying an association between the CISH multiple-SNP score and the accompanying dose-dependent effect on disease susceptibility probably reflect the potential regulatory effect of these polymorphisms within a “multiple-hit model,” whereby each “hit” affects gene expression cumulatively in aggregate. Such a process contrasts with that of structural variants, in which the presence of one deleterious mutation may be sufficient to account for disease.

In the ex vivo study, carriage of the −292 allele reduced CISH expression after stimulation with interleukin-2. However, this study lacked power to detect significant differences in gene expression in persons with 0, 1, 2, 3, and 4 or more risk alleles. Although −292 showed associations with multiple infectious diseases and could be a true functional variant, +1320 showed a stronger association with susceptibility to tuberculosis, and we found this association in each of the tuberculosis studies. Perhaps variation at +1320 affects transcript expression; position +1320 is located in the untranslated portion of exon 2.30

Stimulation by interleukin-2 may enhance microbial and viral replication,31 and its effect may be further dependent on the presence of other immune cells. For example, clinical trials of interleukin-2 infusion in HIV-positive patients have shown different effects on individual persons depending on their CD4+ counts.32,33 Although it is perhaps unexpected that common variation within a single gene influences susceptibility to a diverse range of infectious diseases, there is increasing evidence that disparate infections are recognized by a common host inflammatory pathway.8,34-36

The observation that the risk alleles occur at appreciable allele frequencies in each of the study populations is surprising, given data that suggest an evolutionary selective pressure exerted by some infectious diseases.37,38 One explanation may be that the variant alleles associate with decreased susceptibility against other major causes of death in these populations. For example, immune modulation at the interleukin-2 receptor axis may protect against type 1 diabetes mellitus.39 A possible role of CISH polymorphisms in the development of inflammatory as well as infectious diseases merits further study.

Current clinical management of bacteremia, malaria, and tuberculosis relies primarily on antimicrobial agents that are specifically targeted to the likely pathogen. Our findings implicate CISH in multiple-pathogen susceptibility and raise the possibility that pharmacologic manipulation of the SOCS pathway may have an effect on the treatment of multiple, diverse infectious diseases. CISH variants may also influence responses to existing immunotherapies such as interleukin-2 therapy in renal-cell cancer, which is associated with wide and largely unexplained variations in interindividual response rates.40,41 Study of longitudinal immune responses together with responses to antimicrobial agents and clinical outcome in patients with infectious diseases may further define the risk model for CISH SNPs. The integration of such a model with environmental and other host genetic factors may improve the prediction of treatment responses and disease outcomes.

Supported by grants (to Drs. Khor, Goh, and Hill) and clinical research fellowships (to Drs. Chapman, Williams, Scott, and Berkley) from the Wellcome Trust and the Agency for Science, Technology and Research, Singapore, by the Wellcome Trust Kenya Major Overseas Programme, and by funding from the NIHR Oxford Biomedical Research Centre Programme.

No potential conflict of interest relevant to this article was reported.

Drs. Khor, Vannberg, Chapman, and Guo contributed equally to this article.

This article (10.1056/NEJMoa0905606) was published on May 19, 2010, at NEJM.org.

We thank all the subjects as well as the many investigators involved in the original case–control studies in Gambia, Hong Kong, Kenya, Malawi, and Vietnam for their contributions.

Source Information

Address reprint requests to Dr. Khor at the Division for Infectious Diseases, Genome Institute of Singapore, 60 Biopolis St., Singapore, Singapore, or at ; or to Dr. Hill at the Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Dr., Oxford OX3 7BN, United Kingdom, or at .

The authors' affiliations are listed in the Appendix.

Appendix

The authors' affiliations are as follows: The Wellcome Trust Centre for Human Genetics (C.C.K., F.O.V., S.J.C., S.H.W., D.V., A.R., T.C.M., D.K., A.V.S.H.) and the Centre for Clinical Vaccinology and Tropical Medicine (J.A.S., T.N.W., J.A.B.), University of Oxford, Oxford, United Kingdom; the Host Susceptibility to Infection Program, Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (C.C.K., H.G., K.-Y.T., D.L.M.G.), and the Department of Paediatrics, University Children's Medical Institute, National University Health System and National University of Singapore (S.K.H.T., D.L.M.G.) — all in Singapore; the Section of Genomic Medicine, Imperial College, Hammersmith Hospital (A.J.W.), the Department of Paediatrics and Wellcome Trust Centre for Clinical Tropical Medicine, Faculty of Medicine, Imperial College (K. Marsh, K. Maitland), and the Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine (S.F., P.E.M.F.) — all in London; the Tuberculosis and Chest Service, Department of Health (K.-C.C., C.-C.L., C.-M.T.); the Public Health Laboratory, Department of Health (K.-M.K.); the Department of Microbiology (C.-Y.C.), the Stanley Ho Centre for Emerging Infectious Diseases (J.J.Y.S.), the Department of Chemical Pathology, Faculty of Medicine, and the Laboratory of Genetics of Disease Susceptibility, Li Ka Shing Institute of Health Sciences (N.L.S.T.), Chinese University of Hong Kong; and the Tuberculosis and Chest Unit, Grantham Hospital, Hospital Authority (W.-W.Y.) — all in Hong Kong; the Karonga Prevention Study, Chilumba, Malawi (A.C.C., B.N.); Medical Research Council Laboratories, Gambia (D.K.); Institut de Recherche pour le Développement, Dakar, Senegal (C.L.); the Hospital for Tropical Diseases and Wellcome Trust Major Overseas Programme, Cho Quan Hospital, Ho Chi Minh City, Vietnam (T.-T.H., N.P.D.); and the Kenya Medical Research Institute and Wellcome Trust Programme, Centre for Geographic Medicine Research, Kilifi District Hospital, Kilifi, Kenya (N.P., K. Marsh, K. Maitland, J.A.S., T.N.W., J.A.B.).

References

References

  1. 1

    Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727-732
    Full Text | Web of Science | Medline

  2. 2

    Flynn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 2003;15:450-455
    CrossRef | Web of Science | Medline

  3. 3

    Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129
    CrossRef | Web of Science | Medline

  4. 4

    Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004;72:5630-5637
    CrossRef | Web of Science | Medline

  5. 5

    Aman MJ, Migone TS, Sasaki A, et al. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signalling. J Biol Chem 1999;274:30266-30272
    CrossRef | Web of Science | Medline

  6. 6

    Lin JX, Leonard WJ. Signalling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev 1997;8:313-332
    CrossRef | Medline

  7. 7

    Dooms H, Wolslegel K, Lin P, Abbas AK. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med 2007;204:547-557
    CrossRef | Web of Science | Medline

  8. 8

    Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007;39:523-528
    CrossRef | Web of Science | Medline

  9. 9

    Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 2002;415:673-679
    CrossRef | Web of Science | Medline

  10. 10

    Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78
    CrossRef | Web of Science | Medline

  11. 11

    Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995;377:435-438
    CrossRef | Web of Science | Medline

  12. 12

    Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995;14:2816-2826
    Web of Science | Medline

  13. 13

    Uchida K, Yoshimura A, Inazawa J, et al. Molecular cloning of CISH, chromosome assignment to 3p21.3, and analysis of expression in fetal and adult tissues. Cytogenet Cell Genet 1997;78:209-212
    CrossRef | Medline

  14. 14

    Jin P, Wang E, Provenzano M, et al. Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med 2006;4:26-26
    CrossRef | Web of Science | Medline

  15. 15

    Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev 2004;202:67-83
    CrossRef | Web of Science | Medline

  16. 16

    Matsumoto A, Seki Y, Kubo M, et al. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 1999;19:6396-6407
    Web of Science | Medline

  17. 17

    Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997;89:3148-3154
    Web of Science | Medline

  18. 18

    Nakajima H, Liu X-W, Wynshaw-Boris A, et al. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 1997;7:691-701
    CrossRef | Web of Science | Medline

  19. 19

    Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999;10:249-259
    CrossRef | Web of Science | Medline

  20. 20

    Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005;352:39-47
    Full Text | Web of Science | Medline

  21. 21

    Crampin AC, Mwinuka V, Malema SS, Glynn JR, Fine PE. Field-based random sampling without a sampling frame: control selection for a case-control study in rural Africa. Trans R Soc Trop Med Hyg 2001;95:481-483
    CrossRef | Web of Science | Medline

  22. 22

    Tang NL, Fan HP, Chang KC, et al. Genetic association between a chemokine gene CXCL-10 (IP-10, interferon gamma inducible protein 10) and susceptibility to tuberculosis. Clin Chim Acta 2009;406:98-102
    CrossRef | Web of Science | Medline

  23. 23

    Lienhardt C, Bennett S, Del Prete G, et al. Investigation of environmental and host-related risk factors for tuberculosis in Africa. I. Methodological aspects of a combined design. Am J Epidemiol 2002;155:1066-1073
    CrossRef | Web of Science | Medline

  24. 24

    Hill AV, Allsopp CE, Kwiatkowski D, et al. Common West African HLA antigens are associated with protection from severe malaria. Nature 1991;352:595-600
    CrossRef | Web of Science | Medline

  25. 25

    Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995;332:1399-1404
    Full Text | Web of Science | Medline

  26. 26

    Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265
    CrossRef | Web of Science | Medline

  27. 27

    Mira MT, Alcais A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004;427:636-640
    CrossRef | Web of Science | Medline

  28. 28

    Clayton D. Population association. In: Balding DJ, Bishop M, Cannings C, eds. Handbook of statistical genetics. New York: Wiley, 2003:519-39.

  29. 29

    Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442
    CrossRef | Web of Science | Medline

  30. 30

    Pickering BM, Willis AE. The implications of structured 5′ untranslated regions on translation and disease. Semin Cell Dev Biol 2005;16:39-47
    CrossRef | Web of Science | Medline

  31. 31

    Fauci AS. Host factors in the pathogenesis of HIV disease. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26–29, 1999.

  32. 32

    Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995;332:567-575
    Full Text | Web of Science | Medline

  33. 33

    Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-1356
    Full Text | Web of Science | Medline

  34. 34

    Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003;300:1524-1525
    CrossRef | Web of Science | Medline

  35. 35

    Hawn TR, Dunstan SJ, Thwaites GE, et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 2006;194:1127-1134
    CrossRef | Web of Science | Medline

  36. 36

    Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997;314:1229-1232
    CrossRef | Web of Science | Medline

  37. 37

    Tishkoff SA, Varkonyi R, Cahinhinan N, et al. Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance. Science 2001;293:455-462
    CrossRef | Web of Science | Medline

  38. 38

    Barreiro LB, Ben-Ali M, Quach H, et al. Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet 2009;5:e1000562-e1000562
    CrossRef | Web of Science | Medline

  39. 39

    Chistiakov DA, Voronova NV, Chistiakov PA. The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. Immunol Lett 2008;118:1-5
    CrossRef | Web of Science | Medline

  40. 40

    McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 2007;13:716s-720s
    CrossRef | Web of Science | Medline

  41. 41

    Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008;226:19-28
    CrossRef | Web of Science | Medline

Citing Articles (13)

Citing Articles

  1. 1

    A. V. S. Hill. (2012) Evolution, revolution and heresy in the genetics of infectious disease susceptibility. Philosophical Transactions of the Royal Society B: Biological Sciences 367:1590, 840-849
    CrossRef

  2. 2

    Stephen J. Chapman, Adrian V. S. Hill. (2012) Human genetic susceptibility to infectious disease. Nature Reviews Genetics
    CrossRef

  3. 3

    B. K. Cornes, C. C. Khor, M. E. Nongpiur, L. Xu, W.-T. Tay, Y. Zheng, R. Lavanya, Y. Li, R. Wu, X. Sim, Y.-X. Wang, P. Chen, Y. Y. Teo, K.-S. Chia, M. Seielstad, J. Liu, M. L. Hibberd, C.-Y. Cheng, S.-M. Saw, E.-S. Tai, J. B. Jonas, E. N. Vithana, T. Y. Wong, T. Aung. (2012) Identification of four novel variants that influence central corneal thickness in multi-ethnic Asian populations. Human Molecular Genetics 21:2, 437-445
    CrossRef

  4. 4

    Mohammad Alam Miah, Cheol-Hee Yoon, Joonoh Kim, Jinah Jang, Young-Rim Seong, Yong-Soo Bae. (2012) CISH is induced during DC development and regulates DC-mediated CTL activation. European Journal of Immunology 42:1, 58-68
    CrossRef

  5. 5

    Manfred B. Lutz. (2012) Buy one, get one free: Additional functions of GM-CSF in DC maturation. European Journal of Immunology 42:1, 35-38
    CrossRef

  6. 6

    Hoang V. Tong, Nguyen L. Toan, Le H. Song, Peter G. Kremsner, Jürgen F. J. Kun, Velavan TP. (2011) Association of CISH -292A/T genetic variant with hepatitis B virus infection. Immunogenetics
    CrossRef

  7. 7

    M. Limper, M. D. Kruif, N. E. Ajubi, A. P. Zanten, D. P. M. Brandjes, A. J. Duits, E. C. M. Gorp. (2011) Procalcitonin as a potent marker of bacterial infection in febrile Afro-Caribbean patients at the emergency department. European Journal of Clinical Microbiology & Infectious Diseases 30:7, 831-836
    CrossRef

  8. 8

    Ronan K. Carroll, Samuel A. Shelburne, Randall J. Olsen, Bryce Suber, Pranoti Sahasrabhojane, Muthiah Kumaraswami, Stephen B. Beres, Patrick R. Shea, Anthony R. Flores, James M. Musser. (2011) Naturally occurring single amino acid replacements in a regulatory protein alter streptococcal gene expression and virulence in mice. Journal of Clinical Investigation 121:5, 1956-1968
    CrossRef

  9. 9

    (2011) Case 2-2011: A Woman with Shock after Treatment of a Furuncle. New England Journal of Medicine 364:15, 1477-1479
    Full Text

  10. 10

    Steven P. LaRosa, Steven M. Opal. (2011) Biomarkers: The Future. Critical Care Clinics 27:2, 407-419
    CrossRef

  11. 11

    CHI CHIU LEUNG, DAVID FELLER-KOPMAN, MICHAEL S. NIEDERMAN, STEPHEN G. SPIRO. (2011) Year in review 2010: Tuberculosis, pleural diseases, respiratory infections. Respirology 16:3, 564-573
    CrossRef

  12. 12

    (2010) CISH and Susceptibility to Infectious Diseases. New England Journal of Medicine 363:17, 1675-1677
    Full Text

  13. 13

    Hubert E. Blum. (2010) Individualized medicine 2010. Journal of Cellular and Molecular Medicine 14:9, 2257-2263
    CrossRef

Letters